ArticleTissue engineering and regenerative medicine2025
Mycophenolic Acid Induces Osteogenesis in Tonsil-Derived Mesenchymal Stem Cells through Inhibition of IMPDH and HDAC3.
Article in Tissue engineering and regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMycophenolic acid (MPA) is a well-known inhibitor of inosine monophosphate dehydrogenases (IMPDH), and our previous study also highlighted its inhibitory effects on histone deacetylases (HDACs). This study aims to evaluate MPA as a potential regulator of cell differentiation and to explore its mechanisms as an inhibitor of IMPDHs and HDACs using tonsil-derived mesenchymal stem cells (TMSCs).
methodsTMSCs were treated with MPA at various concentrations for 48 h to evaluate its cytotoxic effects. The MPA treatment conditions were then optimized to induce differentiation of TMSCs. To investigate the underlying mechanisms, protein levels of IMPDH, HDAC3 and the histone acetyltransferase p300 (EP300) were assessed.
resultsMPA even at the highest concentration (160 μM) showed strong cytostatic effects on TMSCs without inducing cell death. Pre-treatment with 10 μM MPA for 48 h promoted osteogenic differentiation while inhibiting adipogenic differentiation. IMPDH inhibition via siRNA mimicked these effects, increasing calcium mineralization in the differentiated TMSCs. Co-treatment with guanosine reversed these effects, highlighting guanine depletion as a key mechanism of inducing osteogenesis. MPA also reduced the protein levels of HDAC3 and histone acetyltransferase p300 (EP300), which were also reversed by guanosine supplementation. The knockdown of HDAC3 or EP300 using siRNAs enhanced osteogenesis, with guanosine reversing these effects. HDAC3 overexpression reversed the effects of MPA, decreasing calcium mineralization.
conclusionThese findings suggest that MPA induces osteogenesis through guanine depletion, and that subsequent inhibition of HDAC3 and EP300 could be potential strategies for treating bone diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.